Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metro-PD1-1708
2024-513470-22-00Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, capecitabine, cyclophosphamide and vinblastine in Nonhematologic neoplasms, embryonal brain tumor, ependymoma and 4 more (3 arms), sponsored by Centre Oscar Lambret. Primary endpoints: Dose-limiting toxicity and Progression-free survival. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
Nonhematologic neoplasmsembryonal brain tumorependymomagliomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on 2024-513470-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513470-22-00.